Details of Disease

Disease Name

Invasive ductal breast carcinoma

breast invasive ductal carcinoma; invasive ductal breast carcinoma; invasive ductal adenocarcinoma; infiltrating ductal carcinoma of the breast; infiltrating ductal carcinoma; ductal adenocarcinoma; infiltrating ductal breast carcinoma; invasive ductal carcinoma, NST; invasive ductal carcinoma of breast; infiltrating ductal carcinoma of breast; invasive ductal carcinoma, No specific type; invasive ductal carcinoma; infiltrating ductal adenocarcinoma; invasive ductal carcinoma of the breast

Definition

The most common type of invasive breast carcinoma, accounting for approximately 70% of breast carcinomas. The gross appearance is usually typical with an irregular stellate outline. Microscopically, randomly arranged epithelial elements are seen. When large sheets of malignant cells are present, necrosis may be seen. With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma. The in situ component is nearly always ductal but occasionally may be lobular or both.

Disease Hierarchy

DISANYTW: Invasive breast carcinoma

DIS15EA5: Ductal carcinoma

DIS43J58: Invasive ductal breast carcinoma

Disease Identifiers

MONDO ID

MONDO_0004953

MESH ID

D018270

UMLS CUI

C1134719

MedGen ID

209548

SNOMED CT ID

408643008

General Information of Disease (ID: DIS43J58)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Tamoxifen	DMLB0EZ	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 44 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CBX7	TTBN3HC	Limited	Altered Expression	[2]
DDX5	TTZKPVC	Limited	Altered Expression	[3]
EGFL7	TT7WD0H	Limited	Altered Expression	[4]
EGLN2	TTMHFRY	Limited	Altered Expression	[5]
HSD17B13	TTDJYZR	Limited	Altered Expression	[6]
HSPE1	TTWYMFE	Limited	Biomarker	[7]
MKI67	TTB4UNG	Limited	Biomarker	[8]
MRC2	TTYVR8M	Limited	Biomarker	[9]
PRLR	TTBPXMA	Limited	Altered Expression	[10]
PTGER1	TTG1QMU	Limited	Biomarker	[11]
PTH1R	TTFPD47	Limited	Biomarker	[12]
PTK6	TT6TH8V	Limited	Altered Expression	[13]
SLC39A6	TTZN1CF	Limited	Altered Expression	[14]
THRA	TTTSEPU	Limited	Altered Expression	[15]
TIGIT	TTWNL74	Limited	Biomarker	[16]
TNFRSF18	TTG6LA7	Limited	Biomarker	[16]
UGCG	TTPHEX3	moderate	Posttranslational Modification	[17]
ATF4	TTQCKWT	Strong	Biomarker	[18]
BRCA2	TTUARD6	Strong	Genetic Variation	[19]
CD1A	TTBGTFN	Strong	Altered Expression	[20]
CDH1	TTLAWO6	Strong	Biomarker	[21]
CLDN4	TTMTS9H	Strong	Biomarker	[22]
DHCR24	TTTK0NH	Strong	Biomarker	[23]
DPEP1	TTYUENF	Strong	Altered Expression	[24]
FABP5	TTNT2S6	Strong	Altered Expression	[25]
FUT3	TTUPAD7	Strong	Biomarker	[26]
KDM2A	TT8XTY2	Strong	Biomarker	[27]
KLB	TTARBVH	Strong	Biomarker	[28]
MAP4K1	TTSHWUP	Strong	Altered Expression	[29]
MCAM	TTHRE05	Strong	Altered Expression	[30]
MKNK1	TTEZAUX	Strong	Biomarker	[31]
MSMB	TTYH1ZK	Strong	Biomarker	[32]
MTA1	TTO4HUS	Strong	Altered Expression	[33]
MUC5AC	TTEL90S	Strong	Biomarker	[34]
NCOA4	TT8OY02	Strong	Biomarker	[35]
NEK2	TT3VZ24	Strong	Altered Expression	[36]
NOP2	TTBLG3H	Strong	Altered Expression	[37]
PAK2	TT279WO	Strong	Altered Expression	[38]
PRKCZ	TTBSN0L	Strong	Altered Expression	[39]
PTGS2	TTVKILB	Strong	Altered Expression	[40]
RASA1	TTPNZ1F	Strong	Biomarker	[41]
SERPINB5	TT1KW50	Strong	Posttranslational Modification	[42]
SULF2	TTLQTHB	Strong	Biomarker	[43]
TMBIM6	TT7QSMG	Strong	ModifyingMutation	[44]
------------------------------------------------------------------------------------


⏷ Show the Full List of 44 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35B2	DT81RKJ	Strong	Altered Expression	[45]
------------------------------------------------------------------------------------

This Disease Is Related to 6 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH4	DEOCWU3	Limited	Biomarker	[46]
FMO2	DEIASEZ	Limited	Altered Expression	[47]
HSD17B12	DE915QP	Limited	Altered Expression	[6]
HSD17B7	DEDMWFX	Limited	Altered Expression	[6]
NDUFS3	DE741FI	Limited	Biomarker	[48]
PNPO	DE3Z1RA	Strong	Biomarker	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DME(s)

This Disease Is Related to 88 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAM12	OTZKOTDB	Limited	Altered Expression	[50]
APOBEC3C	OTPL0AI1	Limited	Genetic Variation	[51]
AQP5	OT77GBY8	Limited	Altered Expression	[52]
ARHGDIA	OTEXWJDO	Limited	Altered Expression	[53]
CHD1L	OT7CZK7C	Limited	Altered Expression	[54]
COP1	OT6J2K12	Limited	Altered Expression	[55]
CSTA	OT1K68KE	Limited	Altered Expression	[56]
CTBP1	OTVYH2DH	Limited	Altered Expression	[57]
DHRS11	OTU3J0ZL	Limited	Altered Expression	[6]
EIF3A	OTFABY9G	Limited	Biomarker	[58]
ELP3	OTT5UKSZ	Limited	Biomarker	[59]
FBL	OTRODIE5	Limited	Biomarker	[60]
FBXO39	OTPRR6SK	Limited	Altered Expression	[61]
FOXF1	OT2CJZ5K	Limited	Posttranslational Modification	[62]
GATAD2B	OTJL128N	Limited	Altered Expression	[3]
GDF10	OTEVXGJ7	Limited	Altered Expression	[63]
HOXD10	OT0NOWU2	Limited	Biomarker	[64]
ILRUN	OTE8FHQD	Limited	Biomarker	[65]
ITIH5	OTP46PZM	Limited	Altered Expression	[66]
MT1E	OTXJKU4Y	Limited	Altered Expression	[67]
MT1F	OTZVUYG1	Limited	Biomarker	[68]
NEURL1	OT2C4P70	Limited	Altered Expression	[69]
NKD1	OTY3MO97	Limited	Altered Expression	[70]
NOB1	OTW0YNSL	Limited	Biomarker	[71]
PLCB2	OTPAHDGO	Limited	Genetic Variation	[72]
POLD3	OTEQEFQ2	Limited	Altered Expression	[3]
PRSS3	OTN3S5YB	Limited	Biomarker	[73]
RAB25	OTW0W6NP	Limited	Altered Expression	[74]
RGN	OTD04KB1	Limited	Biomarker	[75]
RHBDF1	OTCQ7UDS	Limited	Altered Expression	[76]
RHOBTB2	OT2DATFX	Limited	Biomarker	[77]
SAT2	OT28QL7H	Limited	Biomarker	[78]
SEC62	OTCWEL5F	Limited	Biomarker	[79]
SIM2	OT0QWHK4	Limited	Biomarker	[80]
SMAD4	OTWQWCKG	Limited	Altered Expression	[81]
SMR3A	OT6NAJJI	Limited	Genetic Variation	[51]
SOX18	OTPUMHWA	Limited	Altered Expression	[82]
ST8SIA1	OTGND2YZ	Limited	Genetic Variation	[83]
TACC2	OTW4M7HI	Limited	Biomarker	[84]
TCHP	OTVDMHSY	Limited	Biomarker	[85]
TES	OTL8PP6V	Limited	Altered Expression	[86]
CNTROB	OTR7C7NR	moderate	Genetic Variation	[87]
SPA17	OT8J7T7U	moderate	Altered Expression	[88]
ACVR1C	OTOTYERF	Strong	Altered Expression	[89]
ADAMTS20	OTU0EKLN	Strong	Biomarker	[90]
AGR3	OTONJPDP	Strong	Biomarker	[91]
APOC1	OTA58CED	Strong	Genetic Variation	[92]
BAG1	OTRQNIA4	Strong	Biomarker	[93]
BRD8	OTIKS3PC	Strong	Altered Expression	[37]
CDH22	OTQEUWQN	Strong	Altered Expression	[94]
CHCHD2	OTL5PA3Y	Strong	Biomarker	[95]
CNKSR2	OTAGERJ2	Strong	Altered Expression	[96]
COL5A1	OT24078H	Strong	Altered Expression	[97]
COX5B	OTDP94F3	Strong	Altered Expression	[98]
CRABP2	OTY01V9G	Strong	Altered Expression	[25]
CST6	OTZVHJTF	Strong	Altered Expression	[99]
DNAJB6	OTMHIIAN	Strong	Altered Expression	[100]
DNAJC2	OT3JDA0R	Strong	Biomarker	[85]
ESYT1	OTA8NSJF	Strong	Genetic Variation	[101]
GAL3ST1	OTSFFZRD	Strong	Altered Expression	[102]
HNRNPU	OTLQN1E2	Strong	Altered Expression	[37]
IGSF1	OT3XD6U2	Strong	Altered Expression	[37]
INSIG2	OTX4VY51	Strong	Altered Expression	[103]
LMLN	OTQF0JPY	Strong	Biomarker	[32]
LMO4	OT5NDCT9	Strong	Altered Expression	[104]
MUC6	OTPVL723	Strong	Altered Expression	[34]
NAA25	OTS3QVF1	Strong	Altered Expression	[37]
NOP53	OTA2YKO6	Strong	Altered Expression	[105]
NSD3	OT3677ZG	Strong	Biomarker	[106]
NSUN5	OTBN7RS8	Strong	Altered Expression	[37]
NUDT2	OTMHM1DH	Strong	Biomarker	[107]
PCDH10	OT2GIT0E	Strong	Genetic Variation	[108]
PDPN	OTBUV19I	Strong	Altered Expression	[109]
PFKFB4	OTQYEXL2	Strong	Altered Expression	[110]
PIP5K1C	OT3LPG1R	Strong	Biomarker	[111]
POFUT1	OTOBJZIT	Strong	Altered Expression	[112]
PRPF38B	OTQLH551	Strong	Altered Expression	[113]
PTTG1	OTIMYS4W	Strong	Altered Expression	[114]
RB1CC1	OTZK8PFX	Strong	Altered Expression	[115]
RBM39	OTCMPTF9	Strong	Altered Expression	[116]
SMUG1	OT2YIOCQ	Strong	Biomarker	[117]
SMURF2	OT3TRVL7	Strong	Altered Expression	[96]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[32]
TNFAIP8	OT1G9297	Strong	Biomarker	[118]
TNFAIP8L3	OTHSBS1B	Strong	Altered Expression	[119]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[120]
TPM4	OTN4YLYR	Strong	Altered Expression	[121]
NUS1	OT4DQ82L	Definitive	Biomarker	[122]
------------------------------------------------------------------------------------


⏷ Show the Full List of 88 DOT(s)

References

1	Tamoxifen FDA Label
2	Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer.Eur J Cancer. 2010 May;46(8):1438-44. doi: 10.1016/j.ejca.2010.01.033. Epub 2010 Feb 23.
3	Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues.Tumour Biol. 1996;17(1):5-12. doi: 10.1159/000217961.
4	Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer.Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.
5	Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.Breast Cancer Res Treat. 2012 May;133(1):179-88. doi: 10.1007/s10549-011-1750-5. Epub 2011 Aug 30.
6	17 Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.Gynecol Oncol. 2012 Dec;127(3):587-94. doi: 10.1016/j.ygyno.2012.08.010. Epub 2012 Aug 17.
7	High expression of heat shock protein 10 correlates negatively with estrogen/progesterone receptor status and predicts poor prognosis in invasive ductal breast carcinoma.Hum Pathol. 2017 Mar;61:173-180. doi: 10.1016/j.humpath.2016.09.039. Epub 2016 Dec 16.
8	Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.Lab Invest. 2018 Aug;98(8):1076-1083. doi: 10.1038/s41374-018-0064-1. Epub 2018 Jun 1.
9	Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.Int J Cancer. 2002 Apr 10;98(5):656-64. doi: 10.1002/ijc.10227.
10	Blockade of estrogen-stimulated proliferation by a constitutively-active prolactin receptor having lower expression in invasive ductal carcinoma.Cancer Lett. 2015 Mar 28;358(2):152-160. doi: 10.1016/j.canlet.2014.12.031. Epub 2014 Dec 16.
11	Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
12	Type 1 receptor parathyroid hormone (PTH1R) influences breast cancer cell proliferation and apoptosis induced by high levels of glucose.Med Oncol. 2012 Jun;29(2):439-45. doi: 10.1007/s12032-011-9851-x. Epub 2011 Feb 11.
13	HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.Cell Signal. 2013 Sep;25(9):1754-61. doi: 10.1016/j.cellsig.2013.05.010. Epub 2013 May 22.
14	Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients.Int J Cancer. 2005 Dec 20;117(6):961-73. doi: 10.1002/ijc.21235.
15	Thyroid hormone receptor alpha (TRa) tissue expression in ductal invasive breast cancer: A study combining quantitative immunohistochemistry with digital slide image analysis.Eur J Surg Oncol. 2017 Aug;43(8):1428-1432. doi: 10.1016/j.ejso.2017.05.012. Epub 2017 May 25.
16	Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.Oncoimmunology. 2017 Nov 9;7(2):e1387705. doi: 10.1080/2162402X.2017.1387705. eCollection 2018.
17	Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.Oncotarget. 2016 Jun 14;7(24):36755-36766. doi: 10.18632/oncotarget.9337.
18	Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells.Blood. 2004 Mar 1;103(5):1876-82. doi: 10.1182/blood-2003-06-1859. Epub 2003 Nov 6.
19	The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.Breast Cancer. 2019 Sep;26(5):552-561. doi: 10.1007/s12282-019-00955-6. Epub 2019 Feb 28.
20	CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.Histopathology. 2008 Jan;52(2):203-12. doi: 10.1111/j.1365-2559.2007.02919.x.
21	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.
22	Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.Int J Cancer. 2009 May 1;124(9):2088-97. doi: 10.1002/ijc.24159.
23	DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes.Contrast Media Mol Imaging. 2018 Jan 17;2018:5076269. doi: 10.1155/2018/5076269. eCollection 2018.
24	Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments.Oncotarget. 2017 Jul 4;8(27):43866-43877. doi: 10.18632/oncotarget.16704.
25	4-Amino-2-trifluoromethyl-phenyl retinate inhibits proliferation, invasion, and migration of breast cancer cells by independently regulating CRABP2 and FABP5.Drug Des Devel Ther. 2018 Apr 27;12:997-1008. doi: 10.2147/DDDT.S151029. eCollection 2018.
26	Fut3 role in breast invasive ductal carcinoma: Investigating its gene promoter and protein expression.Exp Mol Pathol. 2015 Dec;99(3):409-15. doi: 10.1016/j.yexmp.2015.08.015. Epub 2015 Aug 29.
27	Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.PLoS One. 2014 Jul 16;9(7):e100888. doi: 10.1371/journal.pone.0100888. eCollection 2014.
28	Downregulation of klotho is associated with invasive ductal carcinoma progression.Oncol Lett. 2017 Dec;14(6):7443-7448. doi: 10.3892/ol.2017.7110. Epub 2017 Sep 29.
29	HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinomanot otherwise specified.Mol Med Rep. 2017 Oct;16(4):4634-4642. doi: 10.3892/mmr.2017.7131. Epub 2017 Aug 2.
30	CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression.Mol Carcinog. 2016 Nov;55(11):1560-1572. doi: 10.1002/mc.22409. Epub 2015 Sep 16.
31	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
32	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.Breast Cancer Res. 2013 Aug 23;15(2):R66. doi: 10.1186/bcr3460.
33	Prognostic significance of cyclin D1, -catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.Ann Surg Oncol. 2012 Dec;19(13):4129-39. doi: 10.1245/s10434-012-2541-x. Epub 2012 Aug 3.
34	Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.Cancer Sci. 2017 Sep;108(9):1897-1902. doi: 10.1111/cas.13317. Epub 2017 Aug 8.
35	Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers.Breast Cancer Res Treat. 2001 Jun;67(3):245-53. doi: 10.1023/a:1017938608460.
36	Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer.J Cell Biochem. 2012 Jun;113(6):1904-14. doi: 10.1002/jcb.24059.
37	Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings.Virchows Arch. 2017 Dec;471(6):707-712. doi: 10.1007/s00428-017-2203-2. Epub 2017 Aug 4.
38	Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines.J Biol Chem. 2011 Jun 24;286(25):22291-9. doi: 10.1074/jbc.M111.236596. Epub 2011 May 9.
39	Analysis of PKC- protein levels in normal and malignant breast tissue subtypes.Oncol Lett. 2019 Feb;17(2):1537-1546. doi: 10.3892/ol.2018.9792. Epub 2018 Dec 4.
40	Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.Oncol Lett. 2017 Sep;14(3):2912-2918. doi: 10.3892/ol.2017.6516. Epub 2017 Jul 4.
41	IQ-domain GTPase-activating protein 1 promotes the malignant phenotype of invasive ductal breast carcinoma via canonical Wnt pathway.Tumour Biol. 2017 Jun;39(6):1010428317705769. doi: 10.1177/1010428317705769.
42	Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.Tumour Biol. 2011 Feb;32(1):23-32. doi: 10.1007/s13277-010-0087-8. Epub 2010 Aug 10.
43	Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts.Clin Exp Metastasis. 2013 Apr;30(4):407-15. doi: 10.1007/s10585-012-9546-5. Epub 2013 Feb 15.
44	Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.J Pathol. 2006 Dec;210(4):420-30. doi: 10.1002/path.2071.
45	SLC35B2 expression is associated with a poor prognosis of invasive ductal breast carcinoma.Asian Pac J Cancer Prev. 2014;15(15):6065-70. doi: 10.7314/apjcp.2014.15.15.6065.
46	Pure flat epithelial atypia identified on core needle biopsy does not require excision.Eur J Surg Oncol. 2020 Feb;46(2):235-239. doi: 10.1016/j.ejso.2019.10.029. Epub 2019 Oct 24.
47	High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.Clin Cancer Res. 2006 Jan 15;12(2):345-52. doi: 10.1158/1078-0432.CCR-05-1633.
48	Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma.Biochem Biophys Res Commun. 2011 Sep 9;412(4):590-5. doi: 10.1016/j.bbrc.2011.08.003. Epub 2011 Aug 16.
49	Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development.Aging (Albany NY). 2019 Apr 14;11(7):2151-2176. doi: 10.18632/aging.101908.
50	ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins.Biochem J. 2013 May 15;452(1):97-109. doi: 10.1042/BJ20121558.
51	The Role of Partial Breast Radiation in the Previously Radiated Breast.Am J Clin Oncol. 2019 Dec;42(12):932-936. doi: 10.1097/COC.0000000000000584.
52	Immunohistochemical evalulation of activated Ras and Rac1 as potential downstream effectors of aquaporin-5 in breast cancer invivo.Biochem Biophys Res Commun. 2017 Nov 25;493(3):1210-1216. doi: 10.1016/j.bbrc.2017.09.125. Epub 2017 Sep 25.
53	Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.Int J Oncol. 2010 Feb;36(2):379-86.
54	Chromodomain Helicase/ATPase DNA-Binding Protein 1-Like Gene (CHD1L) Expression and Implications for Invasion and Metastasis of Breast Cancer.PLoS One. 2015 Nov 23;10(11):e0143030. doi: 10.1371/journal.pone.0143030. eCollection 2015.
55	COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1.Oncogene. 2008 Apr 10;27(17):2401-11. doi: 10.1038/sj.onc.1210892. Epub 2007 Oct 29.
56	Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.J Pathol. 2008 Feb;214(3):337-46. doi: 10.1002/path.2265.
57	Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.Mol Carcinog. 2012 Jun;51(6):500-7. doi: 10.1002/mc.20813. Epub 2011 Jun 16.
58	Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.Arch Gynecol Obstet. 1992;251(1):45-50. doi: 10.1007/BF02718277.
59	Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma.Mol Cell Biochem. 2014 Nov;396(1-2):67-77. doi: 10.1007/s11010-014-2143-y. Epub 2014 Aug 23.
60	Differential expression of follistatin and FLRG in human breast proliferative disorders.BMC Cancer. 2009 Sep 9;9:320. doi: 10.1186/1471-2407-9-320.
61	Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines.Asian Pac J Cancer Prev. 2014 Jan;14(11):6625-9. doi: 10.7314/apjcp.2013.14.11.6625.
62	Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer.Cancer Res. 2010 Jul 15;70(14):6047-58. doi: 10.1158/0008-5472.CAN-10-1576. Epub 2010 Jun 29.
63	Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses.Int J Oncol. 2005 Nov;27(5):1425-31.
64	HOXD10 expression in human breast cancer.Tumour Biol. 2014 Nov;35(11):10855-60. doi: 10.1007/s13277-014-2324-z. Epub 2014 Aug 1.
65	A novel biomarker C6orf106 promotes the malignant progression of breast cancer.Tumour Biol. 2015 Sep;36(10):7881-9. doi: 10.1007/s13277-015-3500-5. Epub 2015 May 8.
66	ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer.Cancer Lett. 2004 Feb 10;204(1):69-77. doi: 10.1016/j.canlet.2003.09.011.
67	Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer.Br J Cancer. 2000 Aug;83(3):319-23. doi: 10.1054/bjoc.2000.1276.
68	Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma.Breast Cancer Res Treat. 2001 Apr;66(3):265-72. doi: 10.1023/a:1010658907462.
69	Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?.Arch Pathol Lab Med. 2012 Sep;136(9):993-1000. doi: 10.5858/arpa.2011-0327-OA.
70	NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.Int J Clin Exp Pathol. 2015 Apr 1;8(4):4015-21. eCollection 2015.
71	Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma.Int J Clin Exp Pathol. 2013 Sep 15;6(10):2137-44. eCollection 2013.
72	Ectopic expression of PLC-2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.Mol Carcinog. 2019 May;58(5):708-721. doi: 10.1002/mc.22964. Epub 2019 Jan 16.
73	PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.Oncotarget. 2017 Mar 28;8(13):21444-21453. doi: 10.18632/oncotarget.15590.
74	Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.Tumour Biol. 2012 Oct;33(5):1581-7. doi: 10.1007/s13277-012-0412-5. Epub 2012 May 30.
75	Histopathological and in vivo evidence of regucalcin as a protective molecule in mammary gland carcinogenesis.Exp Cell Res. 2015 Jan 15;330(2):325-335. doi: 10.1016/j.yexcr.2014.08.007. Epub 2014 Aug 13.
76	Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.Mol Cancer Ther. 2008 Jun;7(6):1355-64. doi: 10.1158/1535-7163.MCT-08-0104. Epub 2008 Jun 4.
77	A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.Mol Carcinog. 2010 Mar;49(3):283-9. doi: 10.1002/mc.20598.
78	Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.Anticancer Res. 2010 Jul;30(7):2489-96.
79	Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer.Arch Gynecol Obstet. 2019 May;299(5):1405-1413. doi: 10.1007/s00404-019-05081-4. Epub 2019 Feb 12.
80	ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition.Oncogene. 2019 Apr;38(14):2611-2626. doi: 10.1038/s41388-018-0622-4. Epub 2018 Dec 10.
81	Molecular Characteristics of Pancreatic Ductal Adenocarcinomas with High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) Are Different from Those without High-Grade PanIN.Pathobiology. 2017;84(4):192-201. doi: 10.1159/000455194. Epub 2017 Mar 15.
82	SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).Med Sci Monit. 2019 Aug 20;25:6244-6254. doi: 10.12659/MSM.915729.
83	GD?synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation.Mol Cancer Res. 2010 Nov;8(11):1526-35. doi: 10.1158/1541-7786.MCR-10-0302. Epub 2010 Oct 1.
84	TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation.Cancer Med. 2016 Aug;5(8):1973-82. doi: 10.1002/cam4.736. Epub 2016 Jun 22.
85	Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.Oncotarget. 2018 Jun 19;9(47):28666-28690. doi: 10.18632/oncotarget.25596. eCollection 2018 Jun 19.
86	Testin is a tumor suppressor and prognostic marker in breast cancer.Cancer Sci. 2012 Dec;103(12):2092-101. doi: 10.1111/cas.12020. Epub 2012 Oct 22.
87	Genetic polymorphisms in centrobin and Nek2 are associated with breast cancer susceptibility in a Chinese Han population.Breast Cancer Res Treat. 2012 Nov;136(1):241-51. doi: 10.1007/s10549-012-2244-9. Epub 2012 Sep 23.
88	Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer.Front Oncol. 2019 Jul 31;9:710. doi: 10.3389/fonc.2019.00710. eCollection 2019.
89	Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.Med Oncol. 2012 Dec;29(4):2519-26. doi: 10.1007/s12032-011-0114-7. Epub 2011 Nov 16.
90	Relationship Between ADAMTS8, ADAMTS18, and ADAMTS20 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) Expressions and Tumor Molecular Classification, Clinical Pathological Parameters, and Prognosis in Breast Invasive Ductal Carcinoma.Med Sci Monit. 2018 Jun 3;24:3726-3735. doi: 10.12659/MSM.907310.
91	Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response.Cancer Res Treat. 2020 Jan;52(1):218-245. doi: 10.4143/crt.2019.217. Epub 2019 Jul 8.
92	Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.Cancer Biol Ther. 2005 Mar;4(3):302-7. doi: 10.4161/cbt.4.3.1501. Epub 2005 Mar 23.
93	BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.Br J Cancer. 2009 Jan 13;100(1):123-33. doi: 10.1038/sj.bjc.6604809. Epub 2008 Dec 9.
94	Hypoxia activates cadherin-22 synthesis via eIF4E2 to drive cancer cell migration, invasion and adhesion.Oncogene. 2018 Feb 1;37(5):651-662. doi: 10.1038/onc.2017.372. Epub 2017 Oct 9.
95	Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis.BMC Cancer. 2019 May 2;19(1):411. doi: 10.1186/s12885-019-5575-7.
96	Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.BMC Cancer. 2018 Mar 13;18(1):284. doi: 10.1186/s12885-018-4188-x.
97	Overexpression of collagen type V 1 chain in human breast invasive ductal carcinoma is mediated by TGF-1.Int J Oncol. 2018 May;52(5):1694-1704. doi: 10.3892/ijo.2018.4317. Epub 2018 Mar 15.
98	High expression of COX5B is associated with poor prognosis in breast cancer.Future Oncol. 2017 Aug;13(19):1711-1719. doi: 10.2217/fon-2017-0058. Epub 2017 Jun 8.
99	Cystatin m: a novel candidate tumor suppressor gene for breast cancer.Cancer Res. 2004 Oct 1;64(19):6957-64. doi: 10.1158/0008-5472.CAN-04-0819.
100	Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.
101	Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.
102	Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.Breast Cancer Res. 2018 Nov 6;20(1):133. doi: 10.1186/s13058-018-1058-z.
103	Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia.Cancer Sci. 2011 Jun;102(6):1137-43. doi: 10.1111/j.1349-7006.2011.01936.x. Epub 2011 Apr 27.
104	LIM only 4 is overexpressed in late stage pancreas cancer.Mol Cancer. 2008 Dec 22;7:93. doi: 10.1186/1476-4598-7-93.
105	Downregulation of GLTSCR2 expression is correlated with breast cancer progression.Pathol Res Pract. 2013 Nov;209(11):700-4. doi: 10.1016/j.prp.2013.07.010. Epub 2013 Aug 27.
106	Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.Breast Cancer Res Treat. 2017 Jul;164(2):349-358. doi: 10.1007/s10549-017-4258-9. Epub 2017 May 8.
107	Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011 Apr 15;128(8):1770-82. doi: 10.1002/ijc.25505.
108	Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer.Oncol Lett. 2018 Oct;16(4):4462-4470. doi: 10.3892/ol.2018.9214. Epub 2018 Jul 25.
109	Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer.Surg Today. 2018 Jan;48(1):110-118. doi: 10.1007/s00595-017-1559-x. Epub 2017 Jul 12.
110	High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.Cancer Cell Int. 2019 Jun 18;19:165. doi: 10.1186/s12935-019-0882-2. eCollection 2019.
111	The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast.Oncotarget. 2018 Nov 20;9(91):36358-36370. doi: 10.18632/oncotarget.26357. eCollection 2018 Nov 20.
112	Overexpression of Pofut1 and activated Notch1 may be associated with poor prognosis in breast cancer.Biochem Biophys Res Commun. 2017 Sep 9;491(1):104-111. doi: 10.1016/j.bbrc.2017.07.053. Epub 2017 Jul 11.
113	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.
114	Pituitary tumor-transforming gene 1 is expressed in primary ductal breast carcinoma, lymph node infiltration, and distant metastases.Dis Markers. 2013;35(4):267-72. doi: 10.1155/2013/912304.
115	Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9.
116	CAPER, a novel regulator of human breast cancer progression.Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.
117	Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.Nucl Med Commun. 2019 Oct;40(10):1051-1059. doi: 10.1097/MNM.0000000000001074.
118	Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.Hum Pathol. 2017 Apr;62:40-49. doi: 10.1016/j.humpath.2016.12.020. Epub 2017 Jan 10.
119	TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-B signaling pathways.Oncotarget. 2017 Jul 25;8(30):48889-48904. doi: 10.18632/oncotarget.16522.
120	DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma in Northeast Chinese women.Oncotarget. 2016 Sep 6;7(36):57970-57977. doi: 10.18632/oncotarget.11153.
121	Loss of Tpm4.1 leads to disruption of cell-cell adhesions and invasive behavior in breast epithelial cells via increased Rac1 signaling.Oncotarget. 2017 May 16;8(20):33544-33559. doi: 10.18632/oncotarget.16825.
122	Correlation of Expression of CHI3L1 and Nogo-A and their Role in Angiogenesis in Invasive Ductal Breast Carcinoma.Anticancer Res. 2019 May;39(5):2341-2350. doi: 10.21873/anticanres.13351.